PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25751590-9	2015	Cyclin D1 immunohistochemistry helps distinguish CCSK from blastemal WT and metanephric adenoma and rhabdoid tumors, but not from neuroblastomas and mesoblastic nephromas.	ccsk	49-53	cyclin D1	Homo sapiens	0-9	
22256788-5	2013	We propose that cyclin D1 may be a central molecule in the pathogenesis of CCSK, driven mainly by the sonic hedgehog and the nuclear factor-kappa B pathways and secondarily by the mammalian target of rapamycin complex mTORC2/PI3K/Akt pathway, heat shock protein 90, and possibly phospholipase D1.	ccsk	75-79	cyclin D1	Homo sapiens	16-25	
34673711-4	2021	We aimed to evaluate the utility of cyclin D1 and BCOR immunohistochemistry in differentiating CCSK from its morphologic mimics.	ccsk	95-99	cyclin D1	Homo sapiens	36-45	
34673711-8	2021	Strong, diffuse nuclear immunoreactivity for cyclin D1 and BCOR was noted in 61% (n=11/18) and 83% (n=15/18) of CCSK, respectively, while it was significantly less in WT (n=3/10 for cyclin D1) (n=2/10 for BCOR).	ccsk	112-116	cyclin D1	Homo sapiens	45-54	
34673711-11	2021	CONCLUSION: Our results provide evidence that concurrent immunopositivity with cyclin D1 and BCOR is helpful in distinguishing CCSK from its morphologic mimics.	ccsk	127-131	cyclin D1	Homo sapiens	79-88	
30736802-5	2019	In this study, we aim to determine the usefulness of Cyclin D1 in differentiating between CCSK and other pediatric renal neoplasms and to compare our results with those of recently published studies.	ccsk	90-94	cyclin D1	Homo sapiens	53-62	
30736802-10	2019	RESULTS: Most or all cases of CCSK, neuroblastoma and renal Ewing sarcoma demonstrated diffuse and strong positivity for Cyclin D1.	ccsk	30-34	cyclin D1	Homo sapiens	121-130	
30736802-13	2019	CONCLUSIONS: Cyclin D1 is a sensitive but not specific immunohistochemical marker for CCSK and many other pediatric renal malignant neoplasms as well as for neuroblastoma.	ccsk	86-90	cyclin D1	Homo sapiens	13-22	
30736802-15	2019	However, Cyclin D1 is very helpful in distinguishing between blastema-rich WT and CCSK.	ccsk	82-86	cyclin D1	Homo sapiens	9-18	
25556515-4	2015	As this fusion results in overexpression of cyclin D1 in ESS, we postulated that overexpression would also occur in CCSK; cyclin D1 immunohistochemistry could then be used to differentiate CCSK from other tumours.	ccsk	116-120	cyclin D1	Homo sapiens	44-53	
25556515-4	2015	As this fusion results in overexpression of cyclin D1 in ESS, we postulated that overexpression would also occur in CCSK; cyclin D1 immunohistochemistry could then be used to differentiate CCSK from other tumours.	ccsk	189-193	cyclin D1	Homo sapiens	44-53	
25556515-4	2015	As this fusion results in overexpression of cyclin D1 in ESS, we postulated that overexpression would also occur in CCSK; cyclin D1 immunohistochemistry could then be used to differentiate CCSK from other tumours.	ccsk	189-193	cyclin D1	Homo sapiens	122-131	
25556515-10	2015	CONCLUSIONS: Cyclin D1 is most helpful in distinguishing CCSK from WT, rhabdoid tumour, and some CMNs, but not from neuroblastoma or Ewing sarcomas.	ccsk	57-61	cyclin D1	Homo sapiens	13-22	
25751590-10	2015	Cyclin D1 overexpression in CCSK is not contingent on YWHAE-FAM22 translocation, and cyclin D1 inhibition may potentially be explored as a targeted therapeutic strategy in CCSK.	ccsk	28-32	cyclin D1	Homo sapiens	0-9